Medical News

Gilead Sciences Recalls CMV Drug Vistide for Possible Contamination

February 15, 2013

Gilead Sciences, a bio-pharmaceutical company, has voluntarily recalled Vistide®, a product used to treat cytomegalovirus in AIDS patients, because "particulate matter" was discovered in some vials of the drug. The description of the contaminated product reads: Vistide® -- cidofovir injection, NDC #61958-0101-1, Lot # B120217A, Expiration Date May 2015. Gilead distributed Vistide Lot #B120217A to wholesalers and hospital and retail pharmacies in the United States, Canada, and Europe.

Gilead has contacted all customers by email and letter and will arrange for the return of Vistide product lot # B120217A. U.S. customers should call Stericycle at 1-888-965-5791, Monday to Friday, 8:00 a.m. to 8:00 p.m. Eastern Time to obtain information on returning Vistide product lot # B120217A.

Although Gilead has not reported any complaints "attributable" to the particulate matter in this Vistide lot, the effects of the particulate matter could be severe, depending on the amount injected, size of the particles, and patient condition. Vistide is a colorless, "sterile, hypertonic aqueous solution" that is packaged in glass vials and usually dispensed in hospitals and health care offices. Health care providers should inspect the lot numbers before injecting Vistide, and they should not inject Vistide Lot # B120217A.

Patients should report problems related to this product to their health care providers.
Health professionals and pharmacists may contact Gilead Medical Information at 1-800-GILEAD-5 (1-800-445-3235) [Option 2], Monday to Friday 8:00 a.m. to 5:00 p.m. Pacific Time to ask questions or report adverse reactions.

The U.S. Food and Drug Administration is aware of Gilead's recall of Vistide Lot # B120217A. Patients, health professionals, and pharmacists may report adverse reactions online, by mail, or via fax:
Regular Mail: Use postage-paid, pre-addressed Form FDA 3500 available at: Mail to address on the pre-addressed form.
Fax: 1-800-FDA-0178

Back to other news for February 2013

Adapted from:
The Guardian Express
02.20.2013; Jim Donahue

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.